

An AACR Conference on

Translational Cancer Medicine 2010 (Europe)

March 21-24, 2010 • RAI Exhibition and Convention Centre • Amsterdam, The Netherlands

Conference Chairpersons:

Alexander M.M. Eggermont

Erasmus Medical Center,
Rotterdam, The Netherlands

Susan E. Bates,

National Cancer Institute,
Bethesda, MD, USA



About the Cover:

1. CNS-1 rat glioblastoma cells were infected with high-capacity adenoviral vectors encoding β -galactosidase under the control of a third-generation Tet-On system (image shows expression off). Reprinted from figure 1A: Curtin, JF, et al., *Mol Cancer Ther* 2008;7(3):439-48.

2. Z-score normalized GI_{50} values for intra-panel versus inter-panel sensitivity across complete NCI-60 data set. Reprinted from figure 3: Covell, DG, et al., *Mol Cancer Ther* 2007 6(8):2261-70.

3. All-to-all Tanimoto scores for true positive and true negative compounds for CNS tumor panel. Reprinted from figure 5: Covell, DG, et al., *Mol Cancer Ther* 2007 6(8):2261-70.

4-5. Presence of discrete sunburn cells 1 day after acute UVB exposure on hairless mouse skin. Reprinted from figure 3A: Lai, F-J, et al., *Clin Cancer Res* 2005;11(16):5769-77.

6. *In situ* hybridization of sections of SCCs and epidermal hyperplasia after acute and chronic UVB exposures on hairless mouse skin. Reprinted from figure 3D: Lai, F-J, et al., *Clin Cancer Res* 2005;11(16):5769-77.

7. CNS-1 rat glioblastoma cells were infected with high-capacity adenoviral vectors encoding β -galactosidase under the control of a third-generation Tet-On system (image shows expression on). Reprinted from figure 1A: Curtin, JF, et al., *Mol Cancer Ther* 2008;7(3):439-48.

8. T2-weighted MRI of 9L rat glioma treated with single dose of 26.6 mg/kg BCNU chemotherapy. Reprinted from figure 3: Ross, BD, et al., *Mol Cancer Ther* 2003;2(6):581-7.

Welcome3

Maps4

Committees5

About the AACR6

Awards and Educational Grants7

General Information8

Scientific Program9

Supporters10

Conference Program and Schedule11

Sunday, March 2111

Educational Session 1: Omics and Bioinformatics11

Educational Session 2: Translational and
Clinical Trial Design11

Educational Session 3: GWAS vs. Systems Biology11

Educational Session 4: Functional Imaging:
Getting Beyond FDG-PET11

Keynote Session11

Table of Contents

Monday, March 22	12
Plenary Session 1: Translational Medicine in Breast Cancer Research	12
Poster Session A	12
Concurrent Session 1: Mutations in Malignancy.....	12
Concurrent Session 2: Immunotherapy.....	12
Plenary Session 2: Translational Medicine in Lung Cancer Research.....	12
Tuesday, March 23	13
Plenary Session 3: Translational Medicine in Multiple Myeloma.....	13
Poster Session B	13
Concurrent Session 3: Circulating Tumor Cells and Stem Cells	13
Concurrent Session 4: Pharmacogenomics, Drug Resistance, and Toxicity	13
Plenary Session 4: Immunotherapy: Vaccines	13
Wednesday, March 24	14
Plenary Session 5: Targets Across Tumor Types	14
Plenary Session 6: Resistance to Targeted Therapies.....	14
Plenary Session 7: Epigenetics.....	14
Proceedings	23
Poster Session A	23
Poster Session B	36
Invited Abstracts	50
Abstract Author Index	60

Welcome from the Chairpersons

Dear Colleagues,

On behalf of the American Association for Cancer Research, we would like to welcome you to Amsterdam, The Netherlands, for the fourth conference in the AACR's Translational Cancer Medicine conference series. Conferences in this series bring together and foster discussion and collaboration between clinicians and basic scientists from academia, industry, and government from all over the world. Our goal is to strengthen translational cancer medicine and to reduce the barriers to progress in oncology. Highlighting this program will be a keynote address by René Bernards titled "Finding mechanisms and biomarkers of drug resistance in cancer."

We would like to thank the Scientific Program and Review committees for their help developing such an outstanding program. We are grateful to Underwriting Supporter Amgen, Inc. and Major Supporter Bristol-Myers Squibb Company for their support of this educational activity, and to AstraZeneca; Aflac, Inc.; and the Avon Foundation for their support of the Scholar-in-Training awards and grants.

Best wishes for a fantastic meeting,

Alexander M.M. Eggermont

Susan E. Bates

Map of the RAI Exhibition and Convention Centre

AACR Translational Cancer Medicine 2010 Amsterdam RAI



Committees

Conference Chairpersons:

Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands

Susan E. Bates, National Cancer Institute, Bethesda, MD, USA

Scientific Program Committee:

José Baselga, Vall d'Hebron University Hospital, Barcelona, Spain

Kapil N. Bhalla, Medical College of Georgia, Augusta, GA, USA

Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo, Norway

Stephen J. Chanock, National Cancer Institute, Bethesda, MD, USA

Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom

E. G. Elisabeth de Vries, University Medical Center Groningen, Groningen, The Netherlands

John A. Foekens, Erasmus Medical Center, Rotterdam, The Netherlands

Nadia Harbeck, University of Cologne, Cologne, Germany

Toshihisa Ishikawa, RIKEN Yokohama Institute, Yokohama, Japan

J. Jack Lee, UT M. D. Anderson Cancer Center, Houston, TX, USA

Jennifer A. Low, Genentech, Inc., South San Francisco, CA, USA

Richard M. Marais, Institute of Cancer Research, London, United Kingdom

Julia A. Newton Bishop, University of Leeds, Leeds, United Kingdom

Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy

Marco A. Pierotti, National Cancer Institute, Milan, Italy

Mark J. Ratain, University of Chicago, Chicago, IL, USA

Eddie Reed, University of South Alabama, Mobile, AL, USA

Eric H. Rubin, Merck Research Laboratories, North Wales, PA, USA

Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France

Laura J. van't Veer, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA

Otmar D. Wiestler, German Cancer Research Center, Heidelberg, Germany

John E.L. Wong, National University of Singapore, Singapore

John J. Wright, National Cancer Institute, Rockville, MD, USA

Scientific Review Committee:

Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands

Susan E. Bates, National Cancer Institute, Bethesda, MD, USA

Tito Fojo, NCI-DHHS, Bethesda, MD, USA

Richard M. Marais, Institute of Cancer Research, London, United Kingdom

About the American Association for Cancer Research (AACR)

The American Association for Cancer Research is a professional society of more than 30,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. Founded in 1907, the AACR has as its mission to accelerate the prevention and cure of cancer through research, education, communication, collaboration, and advocacy. The AACR publishes six major peer-reviewed journals: *Cancer Research*; *Clinical Cancer Research*; *Molecular Cancer Therapeutics*; *Molecular Cancer Research*; *Cancer Epidemiology, Biomarkers & Prevention*; and *Cancer Prevention Research*.

The AACR also publishes *CR*, a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. *CR* provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.

The AACR Annual Meeting attracts more than 16,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care.

To foster the training and development of the next generation of cancer researchers, the AACR offers reduced rates for memberships and journal subscriptions to young investigators, a job web site, and special educational programs designed for early-career scientists. The AACR also sponsors career development awards for this group, to ease the transition to faculty status, and funds travel awards for attendance at AACR meetings. Financial assistance from corporate and non-profit partners enables the AACR to offer grants to post-doctoral and clinical fellows working in basic, translational, clinical, and prevention research.

For more information on AACR's mission and activities, please visit the AACR's website, www.aacr.org.

TRANSLATIONAL CANCER MEDICINE 2010 (USA)

July 11-14, 2010 • San Francisco, CA

 American Association
for Cancer Research
www.aacr.org

Awards and Educational Grants

Scholar-in-Training Awards and Grants

Fifteen presenters of abstracts have been selected by the Scientific Review Committee to receive awards or grants to attend this conference. All graduate and medical students, postdoctoral fellows, and physicians-in-training were eligible for consideration. The names of the Scholar-in-Training Awardees and Grantees, their affiliations, and the poster numbers of their abstracts are provided below. AACR sincerely thanks Aflac, Inc., AstraZeneca, and the Avon Foundation for their generous support of these awards and grants.

AACR-Aflac, Inc. Scholar-in-Training Awards

David Barron, Baylor College of Medicine, Houston, TX, USA, B23

Juliann Chmielecki, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA, A18

John S.W. Low, Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore, B33

Nicholas F. Marko, Cleveland Clinic, Cleveland, OH, USA, B8

Michele L. Martin, BC Cancer Agency, Vancouver, BC, Canada, B12

Rebecca C. Obeng, University of Virginia, Charlottesville, VA, USA, B14

April Rose, McGill University, Montreal, QC, Canada, A8

Nathan West, BC Cancer Agency, Victoria, BC, Canada, B13

Julie Ann Woolworth, Medical University of South Carolina, Charleston, SC, USA, B26

AACR-AstraZeneca International Scholar-in-Training Awards

Hadeel Khallouf, University of Heidelberg, Heidelberg, Germany, B15

Raya Leibowitz-Amit, The Chaim Sheba Medical Center, Tel-Hashomer, Israel, A17

Fayaz Malik, Indian Institute of Integrative Medicine, Jammu, India, A13

Sven Rottenberg, The Netherlands Cancer Institute, Amsterdam, The Netherlands, A14

Katharina Tomek, Medical University Vienna, Vienna, Austria, A6

Avon Foundation Scholar-in-Training Grant

Chinmoy K. Bose, Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, India, A19

General Information

Location of the Session Rooms

The conference is being held at the Amsterdam RAI Exhibition and Convention Centre.

Entrance E is the dedicated entrance for this conference.

Amsterdam RAI Exhibition and Convention Centre
Europaplein 22
NL 1078 GZ Amsterdam
Phone: +31 (0)20 549 1212

Plenary Sessions:	Forum
Concurrent Sessions:	E102
Poster Sessions:	Forum Lounge
Catering:	Forum Lounge and Ruby Lounge

Conference Registration

Conference registration will be held in the RAI Forum Lounge. Registration will be open on the following schedule:

Sunday, March 21	08:00-20:00
Monday, March 22	07:30-18:30
Tuesday, March 23	07:30-18:30
Wednesday, March 24	07:30-15:00

Internet Zone

There will be an Internet Zone available for attendees to check their e-mail while away from the office. The Internet Zone will be located in the Forum Lounge (ground level).

Reception and Meals

Opening Reception

The opening reception will be held Sunday, March 21 from 19:00-21:00 in the Ruby Lounge. All registrants are invited to attend. There will be hors d'oeuvres/finger food and beverages served. Conference badges are required.

Coffee Breaks

The coffee breaks will be held in the Forum Lounge (ground level):

Sunday, March 21	17:15-18:00
Monday, March 22	10:30-11:30 and 16:00-16:15
Tuesday, March 23	10:30-11:30 and 15:30-16:00
Wednesday, March 24	10:30-10:45

Lunches

Complimentary lunch is served in the Ruby Lounge (Level 1):

Monday, March 22	12:30-14:00
Tuesday, March 23	12:30-13:30
Wednesday, March 24	12:45-13:45

No Smoking Regulations

In accordance with the Resolution adopted at the 1968 Annual Meeting of the American Association for Cancer Research, registrants must refrain from smoking in all meeting rooms. This regulation applies to all session rooms, including the exhibit and poster area. Additionally, smoking is not permitted in the Amsterdam RAI Exhibition and Convention Centre.

Cell Phones/Beepers

As a courtesy to your colleagues, please turn off your cell phone or beeper, or set it on silent mode before you enter any room in which a lecture session is taking place.

Certificates of Attendance

Certificates of attendance are available at the conference registration desk as of Wednesday, March 24, 08:00.

Assistance for Physically Challenged Registrants

Registrants with special requirements for transportation should notify a member of the AACR staff at the registration desk upon arrival at the conference.

Scientific Program

Lecture Sessions

The program includes seven major Plenary Sessions that are designed to cover major topics in translational cancer medicine. These sessions will be supplemented with four educational sessions at the beginning of the conference, one keynote session, and four concurrent sessions. Please refer to the conference program on pages 11-14 for a complete listing of all sessions.

Poster Sessions

Abstracts will be presented at the two poster sessions on March 22 and 23. Poster sessions will be held in the Forum Lounge according to the following schedule:

Poster Session A	Monday, March 22	10:30-12:30
Poster Session B	Tuesday, March 23	10:30-12:30

All presenters must stand by their posters for at least 90 minutes of the two-hour poster session. Presenters can set up and take down their posters according to the following schedule:

Poster Session A (March 22, 10:30-12:30), set up starting at 17:30 on March 21, take down by 16:00 on March 22;

Poster Session B (March 23, 10:30-12:30), set up starting at 16:30 on March 22, take down by 18:00 on March 23.

Underwriting Supporter



Major Supporter



Supporters for Scholar-in-Training Awards and Grants



Conference Program and Schedule

Sunday, March 21, 2010

13:00-15:00 **Educational Session 1:
Omics and Bioinformatics**
E102

Chairperson: Olli-P. Kallioniemi, Finland Institute for
Molecular Medicine, Helsinki, Finland

**From canceromics research to personalized
cancer therapies**

Olli-P. Kallioniemi, Finland Institute for Molecular Medicine,
Helsinki, Finland

**The role of informatics in translational research:
The interplay of epidemiology, clinical studies, and
discovery research***

Jacob Koehler, Eli Lilly and Company, Indianapolis, IN, USA

Title to be announced

John N. Weinstein, UT M. D. Anderson Cancer Center,
Houston, TX, USA

13:00-15:00 **Educational Session 2:
Translational and Clinical
Trial Design**
Forum

Chairperson: Eric H. Rubin, Merck Research Laboratories,
North Wales, PA, USA

**Approaches to solving the combinations problem in
oncology therapeutics**

Eric H. Rubin, Merck Research Laboratories, North Wales, PA,
USA

Translational genomics in clinical trials

Carlos M. Caldas, Cancer Research UK, Cambridge,
United Kingdom

Title to be announced

Laura J. van't Veer, UCSF Helen Diller Family Comprehensive
Cancer Center, San Francisco, CA, USA

15:15-17:15 **Educational Session 3:
GWAS vs. Systems Biology**
Forum

Chairperson: Stephen J. Chanock, National Cancer
Institute, Bethesda, MD, USA

**Genome-wide association studies in cancer: Insights in
cancer etiology***

Stephen J. Chanock, National Cancer Institute, Bethesda, MD,
USA

**Understanding melanoma using GWAS and systems
biology***

Julia A. Newton Bishop, University of Leeds, Leeds,
United Kingdom

Etiological clues from breast cancer GWAS*

Montserrat Garcia-Closas, NCI-DCEG, Rockville, MD, USA

15:15-17:15 **Educational Session 4:
Functional Imaging: Getting
Beyond FDG-PET**
E102

Chairperson: E. G. Elisabeth de Vries, University Center,
Groningen, The Netherlands

Functional imaging: Beyond FDG*

Patricia M. Price, Christie Hospital NHS Trust, Manchester,
United Kingdom

Functional imaging: Getting beyond FDG-PET*

E. G. Elisabeth de Vries, University Medical Center Groningen,
Groningen, The Netherlands

PET tracer for therapy monitoring*

Hans-Jürgen Wester, Technische Universität München,
Munich, Germany

17:15-18:00 **Coffee Break**
Forum Lounge

18:00-19:00 **Keynote Session**
Forum

Chairpersons: Alexander M.M. Eggermont, Erasmus
Medical Center, Rotterdam, The Netherlands and **Susan E.
Bates**, National Cancer Institute, Bethesda, MD, USA

**Finding mechanisms and biomarkers of drug resistance
in cancer***

René Bernards, Netherlands Cancer Institute, Amsterdam,
The Netherlands

19:00-21:00 **Opening Reception**
Ruby Lounge

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Conference Program and Schedule

Monday, March 22, 2010

08:30-10:30 **Plenary Session 1:
Translational Medicine in
Breast Cancer Research
Forum**

Chairperson: Nadia Harbeck, University of Cologne, Cologne, Germany

Targeting PI3K in breast cancer
José Baselga, Vall d'Hebron University Hospital, Barcelona, Spain

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients*
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo, Norway

Amplifying the apoptotic actions of estrogen to treat metastatic breast cancer
V. Craig Jordan, Lombardi Comprehensive Cancer Center, Washington, DC, USA

10:30-11:30 **Coffee Break**
Forum Lounge

10:30-12:30 **Poster Session A**
Forum Lounge

12:30-14:00 **Lunch/Networking Break**
Ruby Lounge

14:00-16:00 **Concurrent Session 1:
Mutations in Malignancy
Forum**

Chairperson: Marco A. Pierotti, National Cancer Institute, Milan, Italy

Target mutation: The dark side of the targeted therapies*
Marco A. Pierotti, National Cancer Institute, Milan, Italy

Genetic alterations in melanoma: Implications for disease classification and therapy stratification
Boris C. Bastian, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Mutations and expression profile to guide treatment in sarcomas and GIST*
Jean-Yves Blay, INSERM U-453, Lyon, France

14:00-16:00 **Concurrent Session 2:
Immunotherapy
E102**

Chairperson: Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

Personalized chemotherapy of cancer based on immune parameters*
Laurence Zitvogel, Institute Gustave-Roussy, Villejuif, France

Adoptive T cell transfer: Autografting cultured, specific T cells to treat cancer James Chung-Yin Yang, National Cancer Institute, Bethesda, MD, USA

Development of therapeutic cancer vaccine and construction of clinical research network in Japan*
Yusuke Nakamura, University of Tokyo Human Genome Center, Tokyo, Japan

16:00-16:15 **Coffee Break**
Forum Lounge

16:15-18:15 **Plenary Session 2:
Translational Medicine
in Lung Cancer Research
Forum**

Chairperson: Giuseppe Giaccone, National Cancer Institute, Bethesda, MD, USA

The impact of genomic changes on the treatment of lung cancer*
Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA, USA

The genomic landscape in lung cancer*
Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias I Pujol, Badalona, Spain

Small cell lung cancer: A forgotten disease?
Giuseppe Giaccone, National Cancer Institute, Bethesda, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Conference Program and Schedule

Tuesday, March 23, 2010

08:30-10:30

**Plenary Session 3:
Translational Medicine
in Multiple Myeloma
Forum**

Chairperson: Jesús F. San Miguel, University of Salamanca, Salamanca, Spain

Biology of myeloma: Basis for novel drugs*
Jesús F. San Miguel, University of Salamanca, Salamanca, Spain

Translating multiple myeloma stem cells*
William H. Matsui, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Targeting the ubiquitin-proteasome pathway in myeloma therapy
Robert Z. Orlowski, UT M. D. Anderson Cancer Center, Houston, TX, USA

10:30-11:30

Coffee Break
Forum Lounge

10:30-12:30

Poster Session B
Forum Lounge

12:30-13:30

Lunch
Ruby Lounge

13:30-15:30

**Concurrent Session 3:
Circulating Tumor Cells
and Stem Cells
Forum**

Chairperson: Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Detection, clinical relevance, and molecular characteristics of circulating tumor cells*
Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Enumeration and characterization of CTCs*
Stefan Sleijfer, Erasmus Medical Center, Rotterdam, The Netherlands

Molecular analysis of single disseminated tumor cells
Christoph A. Klein, University of Regensburg, Regensburg, Germany

Molecular characterization of circulating tumor cells in breast cancer

Minetta C. Liu, Lombardi Comprehensive Cancer Center, Washington, DC, USA

13:30-15:30

**Concurrent Session 4:
Pharmacogenomics, Drug
Resistance, and Toxicity
E102**

Chairperson: Eddie Reed, University of South Alabama, Mobile, AL, USA

Pharmacogenetic considerations with molecularly targeted therapy
Sharyn D. Baker, St. Jude Children's Research Hospital, Memphis, TN, USA

Genome-wide discovery and clinical validation of pharmacogenomic markers for chemotherapy*
R. Stephanie Huang, University of Chicago, Chicago, IL, USA

Genetic polymorphisms of ABC transporters in cancer chemotherapy: Development of SmartAmp2 method for clinical genetic testing*
Toshihisa Ishikawa, RIKEN Yokohama Institute, Yokohama, Japan

Factors that influence the regulation of ERCC1 in drug resistant cells*
Eddie Reed, University of South Alabama, Mobile, AL, USA

15:30-16:00

Coffee Break
Forum Lounge

16:00-18:30

**Plenary Session 4:
Immunotherapy: Vaccines
Forum**

Chairperson: Laurence Zitvogel, Institute Gustave-Roussy, Villejuif, France

Immunostimulation versus immunosuppression: The woes of cancer vaccine development
Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands

Therapeutic vaccines for prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Conference Program and Schedule

Augmenting the immune response to prostate cancer with CTLA-4 blockade

Eric J. Small, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

A new era for dendritic cell vaccines

Gerold Schuler, University Hospital of Erlangen, Erlangen, Germany

Immunotherapy of established lesions caused by high-risk HPV*

Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

Wednesday, March 24, 2010

08:30-10:30

Plenary Session 5: Targets Across Tumor Types Forum

Chairperson: Keith T. Flaherty, Massachusetts General Hospital, Boston, MA, USA

Targeting the nexus of heat shock and metabolic stress responses in cancer*

Kapil N. Bhalla, Medical College of Georgia, Augusta, GA, USA

BRAF mutant melanoma as the proving ground for the MAP kinase pathway as a therapeutic target

Keith T. Flaherty, Massachusetts General Hospital, Boston, MA, USA

Hedgehog pathway inhibitors in cancer

Josina C. Reddy, Genentech, Inc., South San Francisco, CA, USA

Targeting DNA repair mechanisms

E. Ruth Plummer, Northern Centre for Cancer Treatment, Newcastle upon Tyne, United Kingdom

10:30-10:45

Coffee Break Forum Lounge

10:45-12:45

Plenary Session 6: Resistance to Targeted Therapies Forum

Chairperson: Tito Fojo, NCI-DHHS, Bethesda, MD, USA

Resistance to targeted therapies in a realistic mouse breast cancer model*

Piet Borst, Netherlands Cancer Institute, Amsterdam, The Netherlands

Resistance to VEGF-targeted therapies

Napoleone Ferrara, Genentech, Inc., South San Francisco, CA, USA

Antibody-initiated cancer immunotherapy*

Louis M. Weiner, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA

Title to be announced

Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

12:45-14:00

Lunch Ruby Lounge

14:00-15:30

Plenary Session 7: Epigenetics Forum

Chairperson: Susan E. Bates, National Cancer Institute, Bethesda, MD, USA

Cancer epigenetics: From DNA methylation to microRNAs

Manel Esteller, Hospital Duran i Reynals, Barcelona, Spain

Targeting histone methyl transferase and demethylases in cancer

Kristian Helin, University of Copenhagen, Copenhagen, Denmark

HDAC inhibitor activity in lymphomas and resistance in solid tumors: Overcoming the impasse

Susan E. Bates, National Cancer Institute, Bethesda, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.